Want to see EMBC full AI Analyst Report?
EMBC Stock Chart & Stats
$9.78
$0.16(0.83%)
At close: 4:00 PM EST
$9.78
$0.16(0.83%)
Day’s Range― - ―
52-Week Range$2.77 - $15.55
Previous CloseN/A
Volume119.84K
Average Volume (3M)2.04M
Market Cap
$195.19M
Enterprise Value$1.70K
Total Cash (Recent Filing)$184.90M
Total Debt (Recent Filing)$1.36B
Price to Earnings (P/E)1.7
Beta0.59
Next Earnings
Aug 07, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend Yield13.98%
Share Statistics
EPS (TTM)1.91
Shares Outstanding59,327,680
10 Day Avg. Volume1,215,714
30 Day Avg. Volume2,041,617
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-1.26
Price to Sales (P/S)0.76
P/FCF Ratio4.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$4.00Price Target Upside-59.10% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)1.59
Revenue Forecast (FY)$1.02B
Bulls Say, Bears Say
Bulls Say
Consumable, Recurring RevenueEmbecta’s core products are disposable insulin delivery consumables, which produce repeat purchasing and predictable baseline demand. Durable chronic‑care consumption supports recurring revenue, stable refill cycles, and a defensible cash flow base versus one‑time device sales, aiding medium‑term revenue resilience.
Strong Recent Cash GenerationTrailing cash conversion is solid, with FCF nearly matching net income, providing capacity to fund operations, deleveraging and targeted investments. While prior years were uneven, current FCF levels materially support debt repayment plans and strategic moves without sole reliance on equity markets.
Acquisition Expands Addressable MarketThe Owen Mumford deal broadens Embecta’s product portfolio into auto‑injectors and new chronic care categories, diversifying revenue away from pen needles. Access to Aidaptus and OM’s IP/commercial channels increases long‑term TAM exposure and potential margin uplift as integration matures and cross‑sell scales.
Bears Say
High Leverage & Negative EquityEmbecta’s capital structure is stressed: significant debt against negative equity constrains strategic flexibility, elevates refinancing and covenant risk, and limits capacity for large discretionary investments. This structurally increases downside risk over the medium term if cash flow weakens or interest costs rise.
Large Product Declines, U.S. Share LossSharp, concentrated share losses in pen needles and steep U.S. declines suggest durable competitive or channel shifts rather than a temporary blip. Loss of a major customer and channel volume softness can persist and structurally reduce scale economics, pricing leverage and revenue predictability for multiple quarters.
Material Guidance, Margin And FCF CutsSignificant downward guidance on revenue, margins and free cash flow signals weaker underlying demand, pricing pressure and one‑time integration costs. Lower structural margins and reduced FCF limit cushion for debt repayment and reinvestment, increasing execution risk for strategic initiatives like integrations and new product launches.
Embecta Corporation News
EMBC FAQ
What was Embecta Corporation’s price range in the past 12 months?
Embecta Corporation lowest stock price was $2.77 and its highest was $15.55 in the past 12 months.
What is Embecta Corporation’s market cap?
Embecta Corporation’s market cap is $195.19M.
When is Embecta Corporation’s upcoming earnings report date?
Embecta Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 11 days.
How were Embecta Corporation’s earnings last quarter?
Embecta Corporation released its earnings results on May 05, 2026. The company reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.417 by -$0.147.
Is Embecta Corporation overvalued?
According to Wall Street analysts Embecta Corporation’s price is currently Overvalued.
Does Embecta Corporation pay dividends?
Embecta Corporation pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 13.98%. See more information on Embecta Corporation dividends here
What is Embecta Corporation’s EPS estimate?
Embecta Corporation’s EPS estimate is 0.27.
How many shares outstanding does Embecta Corporation have?
Embecta Corporation has 59,327,680 shares outstanding.
What happened to Embecta Corporation’s price movement after its last earnings report?
Embecta Corporation reported an EPS of $0.27 in its last earnings report, missing expectations of $0.417. Following the earnings report the stock price went down -57.835%.
Which hedge fund is a major shareholder of Embecta Corporation?
Currently, no hedge funds are holding shares in EMBC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Embecta Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$4.00 (-59.10% Downside)
$4.00 (-59.10% Downside)
Blogger Sentiment
Bearish
EMBC Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 825.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 12.9%
Last 30 Days ▼ 12.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.88%
12-Months-Change
Fundamentals
Return on Equity
13.98%
Trailing 12-Months
Asset Growth
-8.11%
Trailing 12-Months
Company Description
Embecta Corporation
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
EMBC Company Deck
EMBC Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presents meaningful strategic progress (Owen Mumford acquisition, GLP‑1 B2B traction, brand transition progress, debt repayment and a share buyback authorization) but was dominated by substantial near‑term operational and financial setbacks: large revenue declines (especially in the U.S. and pen needles), sharp margin and EPS guide cuts, a GAAP net loss in the quarter, and material reductions in free cash flow guidance. Management has initiated cost/organization reviews and highlighted actions underway, but the magnitude and persistence of the U.S. share loss and market volume softness create significant short‑term headwinds.View all EMBC earnings summariesEMBC Stock 12 Month Forecast
Average Price Target
$4.00
▼(-59.10% Downside)
Technical Analysis
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Ownership Overview
3.24% Insiders
29.04% Mutual Funds
0.88% Other Institutional Investors
52.90% Public Companies and
Individual Investors